22nd Dec 2008 07:00
Sinclair Pharma announces sales collaboration with York Pharma
22nd December 2008, Godalming, UK: Sinclair Pharma plc ("Sinclair": SPH:L), the international specialty pharmaceutical company, announces today that it has entered into a commercial collaboration with York Pharma in the UK. Under the terms of the agreement each company will co-promote selected products to dermatologists and selected GP's.
Sinclair Pharma's sales force will co-promote certain York Pharma products including the anti-acne product Zindaclin and the emollient QV. York Pharma's sales force will co-market Sinclair's Atopiclair product for atopic dermatitis. The agreement comes into force in January 2009 and relates specifically to the UK market.
Dr Michael Flynn, CEO of Sinclair Pharma said:
"This agreement effectively doubles the number of specialist salespersons promoting the two companies' dermatology product in the UK. For Sinclair this is particularly important for the promotion of our reimbursed product Atopiclair for the treatment of atopic dermatitis. We are exploring similar synergies with York in other European countries"
Terry Sadler, Chief Executive of York Pharma, added:
"We're delighted to be working with Sinclair Pharma, initially in the UK market, where York has a number of approved products which can be promoted to both GP's and Dermatologists. We believe this collaboration will help optimise the value of York Pharma's portfolio and accelerate our sales growth ahead of the anticipated commercialisation of Abasol in the UK in 2009."
In addition to the agreement announced today, discussions between the two companies are ongoing to evaluate the expansion of the co-marketing relationship into other key European territories.
-ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Mariyam Rawat, Communications & Investor relations [email protected]
Capital MS&L
Mary Clark, Anna Mitchell Tel +44 (0)20 7307 5340
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 80 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short timeframe. Sinclair focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.
About York Pharma PLC www.yorkpharma.com
YORK PHARMA PLC is a pharmaceutical Group, established in 2003, which develops, markets and supplies branded dermatological products to pharmaceutical wholesalers, hospitals and general practitioners within the field of dermatology.
The Group currently has at its disposal more than 20 patent families (with over 100 individual patents/patent applications) and intellectual property in relation to its portfolio of novel dermatology products and technology platforms in the key therapeutic areas of fungal infection, eczema, psoriasis, vitiligo and acne that make up more than 87% of the global $10bn dermatology market.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma